Immunity from prior infection or vaccination against SARS-CoV-2 creates a broader 'immunity shield' against related sarbecoviruses, potentially slowing or preventing the emergence of a novel virus in humans.

Vaccines are most effective when deployed promptly after the first SARS-CoV-X case is detected, with delays likely reducing impact.

A study from the MRC‑University of Glasgow Centre for Virus Research analyzes population immunity to SARS-type viruses and its potential to reduce future coronavirus pandemic risk.

The research, published in Nature Communications, examines post-pandemic changes in population immunity and its impact on reducing the likelihood of zoonotic coronavirus emergence.

Funding for the study came from UK Research and Innovation bodies: the Medical Research Council (MRC) and the Biotechnology and Biological Sciences Research Council (BBSRC).

Pablo Murcia and Brian Willett from CVR describe the protective effect of population immunity as a biological barrier, while cautioning it is not a guarantee against all future threats.

CVR researchers Pablo Murcia and Brian Willett emphasize that population‑level immunity provides protection and that timely vaccination campaigns amplify this effect against any emerging coronavirus threat.

The study notes that delaying vaccination would likely lessen its effectiveness in preventing transmission.